Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis
Completed
Novartis Pharmaceuticals
Phase 2
2008-12-01
Loading dose, four arm, double-blind, parallel group, placebo-controlled study comparing
single and multiple doses of AIN457 to placebo in patients with a diagnosis of moderate to
severe chronic plaque psoriasis.
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
Completed
Novartis Pharmaceuticals
Phase 2
2009-07-01
This study will assess at Week 16 the efficacy and safety of AIN457 at different doses in
patients with active RA despite stable MTX therapy. Treatment will continue up to Week 48
with a safety follow-up at Week 60 to assess the long term efficacy and safety of AIN457
treatment in combination with MTX in RA.
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
Completed
Novartis Pharmaceuticals
Phase 2
2009-07-01
The purpose of the study is to determine whether, in patients with moderate to severe
plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis
symptoms and the extent to which the patient's body area is affected by the disease (compared
to placebo).
16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis
Completed
Novartis Pharmaceuticals
Phase 3
2011-10-01
This study will assess the efficacy and safety of secukinumab in patients with active
ankylosing spondylitis who are intolerant to or have had an inadequate response to NSAIDs,
DMARDs and / or TNFα inhibitor therapy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
